

ASX ANNOUNCEMENT

30 August 2023

Annual General Meeting Results – Additional Information



Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") in accordance with ASX Listing Rule 3.13.2 (d) hereby provides, further to the previously announced results of its Annual General Meeting of shareholders held on 29 August 2023, the percentage of the total number of securities that were voted on each resolution on the following page. The Company confirms the results have not changed from the Company's announcement on 29 August 2023.

ENDS

BY ORDER OF THE COMPANY SECRETARY

A handwritten signature in black ink, appearing to be "Alistair Warren".

Alistair Warren
Company Secretary

Proxy Results

Resolution	For	Against	Abstain	Chairman's discretion
1	42,438,141 97.44%	648,475 1.49%	201,422 -	465,126 1.07%
2	45,068,853 97.78%	561,182 1.22%	425,527 -	462,494 1.00%
3	44,899,630 97.31%	758,617 1.64%	379,580 -	480,229 1.04%
4(a)	41,406,498 95.46%	1,506,065 3.47%	2,065,877 -	463,494 1.07%
4(b)	41,418,984 95.51%	1,461,245 3.37%	511,883 -	487,494 1.12%
4(c)	41,435,948 95.50%	1,492,042 3.44%	363,000 -	462,494 1.07%
5	41,451,077 95.43%	1,497,142 3.45%	1,217,771 -	487,494 1.12%
6	41,418,374 95.50%	1,487,142 3.43%	385,474 -	462,494 1.07%
7(a)	39,940,731 95.12%	1,553,851 3.70%	379,929 -	493,792 1.18%
7(b)	39,988,231 95.28%	1,517,148 3.61%	397,798 -	465,126 1.11%
8	41,557,891 95.82%	1,338,056 3.09%	380,719 -	474,126 1.09%

Poll Results

Resolution	For	Against	Abstain
1 – Remuneration report	42,903,267 98.51%	648,475 1.49%	201,422 -
2 – Re-election of Director – Dr Neale Fong	77,640,227 99.28%	561,182 0.72%	425,527 -
3 – Approval of 10% placement capacity	77,488,739 99.03%	758,617 0.97%	379,580 -
4(a) – Approval of issue of Non-Executive Retention Rights – Michael Lynch-Bell	41,869,992 96.53%	1,506,065 3.47%	2,065,877 -
4(b) – Approval of issue of Non-Executive Retention Rights – Dr Neale Fong	41,906,478 96.63%	1,461,245 3.37%	511,883 -
4(c) – Approval of issue of Non-Executive Retention Rights – Beatriz Vicen Banzo	41,898,442 96.56%	1,492,042 3.44%	363,000 -
5 – Approval of issue of Executive Retention Rights – Fleta Solomon	41,938,571 96.55%	1,497,142 3.45%	1,217,771 -
6 – Approval of issue of Executive Retention Rights – Angus Caithness	41,880,868 96.57%	1,487,142 3.43%	385,474 -
7(a) – Ratification of issue of Placement Shares – 777,007 Shares under Listing Rule 7.1	72,543,403 97.90%	1,553,851 2.10%	379,929 -
7(b) – Ratification of issue of Placement Shares – 27,000,771 Shares under Listing Rule 7.1A	72,562,237 97.95%	1,517,148 2.05%	397,798 -
8 – Approval of issue of Director Placement Shares	53,481,458 97.56%	1,338,056 2.44%	380,719 -

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Paul Long
Chief Executive Officer
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, with its Danish facility being one of the largest GMP medicinal cannabis production sites in Europe (if not the largest) and its West Australia site a premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

